About QuidelOrtho Corporation

QuidelOrtho Corporation, formed through the 2022 merger of Quidel Corporation and Ortho Clinical Diagnostics, combines over 100 years of collective diagnostic innovation to create a comprehensive diagnostics leader. The combined company leverages complementary strengths in point-of-care testing, molecular diagnostics, and clinical laboratory solutions to serve the full continuum of diagnostic testing needs. QDEL stock price reflects the company's transformation into a scaled diagnostics platform with enhanced capabilities across testing environments.

Led by CEO Douglas Bryant, who brings extensive diagnostics industry experience, QuidelOrtho has focused on integrating operations while maintaining innovation momentum across its product portfolio. The management team combines expertise from both legacy companies to drive synergies and accelerate growth initiatives. Leadership's strategic vision for creating a differentiated diagnostics company with broad capabilities has been important for realizing merger benefits and influencing QDEL stock price trajectory.

QuidelOrtho operates across major diagnostic testing categories including immunoassays, molecular diagnostics, point-of-care tests, and clinical chemistry solutions. The company serves hospitals, clinical laboratories, physician offices, and urgent care clinics with a comprehensive portfolio addressing infectious diseases, women's health, cardiovascular conditions, and general wellness testing. With diagnostic testing remaining essential to healthcare delivery, increasing demand for rapid and accurate testing solutions, and significant synergy opportunities from the merger, QDEL offers investors exposure to a transformed diagnostics leader with enhanced scale and capabilities, though integration execution remains key to realizing full potential.